Trexquant Investment LP Invests $6.50 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Trexquant Investment LP bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 135,873 shares of the biopharmaceutical company’s stock, valued at approximately $6,496,000. Trexquant Investment LP owned about 0.11% of Halozyme Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HALO. Norges Bank acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at about $60,054,000. Arrowstreet Capital Limited Partnership increased its holdings in Halozyme Therapeutics by 141.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company’s stock worth $47,470,000 after buying an additional 581,475 shares during the period. Raymond James Financial Inc. purchased a new position in Halozyme Therapeutics during the 4th quarter worth approximately $21,838,000. Vanguard Group Inc. lifted its stake in Halozyme Therapeutics by 3.0% during the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after acquiring an additional 386,618 shares during the period. Finally, Janney Montgomery Scott LLC increased its stake in shares of Halozyme Therapeutics by 698.8% in the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock worth $13,756,000 after acquiring an additional 251,711 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HALO. Benchmark restated a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Finally, Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $59.77 on Friday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The firm has a fifty day moving average of $59.82 and a 200 day moving average of $54.93. The firm has a market cap of $7.38 billion, a PE ratio of 17.43, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,200 shares of company stock valued at $1,786,668 over the last ninety days. Insiders own 2.90% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.